Overview
- Explores the development and use of angiogenesis and tyrosine kinase inhibitors in epithelial renal tumor treatment
- Presents the latest findings in the field of molecular medicine and the exploration of novel targets as therapies for renal cell carcinomas
- Provides substantive background on the research data and clinical findings of the latest gene therapy studies
- Includes supplementary material: sn.pub/extras
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (25 chapters)
-
Front Matter
Keywords
About this book
In the second edition of their critically acclaimed book, Ronald Bukowski, Robert Motzer, and Robert Figlin have thoroughly updated and expanded their survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. A panel of internationally renowned contributors explores the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors. The discussion includes the specific biology of selected target molecules or receptors and the various agents that inhibit these targets, including full chapters devoted to drugs that selectively inhibit receptor tyrosine kinases, such as sunitinib and axitinib. Further attention is paid to leading-edge strategies that target and inhibit tumor associated angiogenesis and block the vascular endothelial growth factor pathway. Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Second Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by the pioneers of the field.
Reviews
From the reviews of the second edition:
"Chapters in this book are written by an authoritative group of contributors who are well known for their translational and clinical work in kidney cancer. … The primary audience includes individuals on the cusp of translational … in kidney cancer. … for most practicing medical oncologists, the book provides essential data upon which their daily clinical decisions are based when caring for patients afflicted with kidney cancer. … The strength of this book lies in … its sharp insights into a rapidly evolving field." (Robert G Uzzo, Doody’s Review Service, June, 2009)
Editors and Affiliations
Bibliographic Information
Book Title: Renal Cell Carcinoma
Book Subtitle: Molecular Targets and Clinical Applications, Second Edition
Editors: Ronald M. Bukowski, Robert A. Figlin, Robert J. Motzer
DOI: https://doi.org/10.1007/978-1-59745-332-5
Publisher: Humana Totowa, NJ
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Humana Press 2009
Softcover ISBN: 978-1-60761-468-5Due: 17 March 2010
eBook ISBN: 978-1-59745-332-5Published: 08 February 2009
Edition Number: 2
Number of Pages: XVIII, 506
Number of Illustrations: 25 illustrations in colour
Topics: Oncology, Nuclear Medicine